Radar · Life Sciences Tech in New York
Best Life Sciences Tech Companies in New York, United States
The 167 best Life Sciences Tech companies in New York, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Formation Bio.
By Riya SenguptaFinancials
167companies tracked
$4.1Bdisclosed funding
2unicorns
90have raised
FLIAR INTELLIGENCE · LIFE SCIENCES TECH × NEW YORK
Our analysis of 50 Life Sciences Tech companies
$9.6b in tracked funding; 89% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
89%cloud-native stacks
2025funding peak (by rounds)
8unicorns
2018median founding year
558kcombined LinkedIn audience
37%of audience held by top 3
3companies hiring publicly (12 mo)
Ranked: Best Life Sciences Tech companies in New York
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Formation Bio 🦄 Provider of AI-powered drug discovery platform for various diseases | $608M | 24 mo ago | Series D | — | Benjamine Liu Co-Founder & CEO | — | — |
| 2 | Komodo Health 🦄 AI and cloud-based platforms provide data-driven insights to healthcare providers | $514M | 43 mo ago | Series E | 269 | Arif Nathoo Co-Founder & CEO | — | 1 partnership · 1 expansion |
| 3 | Recursion Pharmaceuticals AI-enabled drug discovery and development platform for novel therapeutics | $452M | 35 mo ago | Public | 400 | Dean Li Co-Founder and Board Member | 203 patents AI-driven drug discovery: ML models for bioactivity, phenomics, and active learning | — |
| 4 | H1 Provider of medical affair services for biopharma and medical device industry | $302M | 48 mo ago | Series C | 480 | Ian Sax Co-Founder | — | 1 launch · 1 award |
| 5 | PAIGE Developer of AI applications and foundation models for cancer diagnostics | $239M | 41 mo ago | Acquired | 133 | David Klimstra Co-Founder | 540 patents AI-driven digital pathology and image analysis for cancer biomarker detection | — |
| 6 | Paradigm Provider of clinical research healthcare services | $203M | 40 mo ago | Series A | 99 | Kent Thoelke Chief Executive Officer | 29 patents Secure digital credential issuance and verification for government, construction, and IoT devices. | — |
| 7 | Schrodinger Provider of a web-based simulation and modelling tool | $162M | 55 mo ago | Acquired | 625 625 → 1,003 (+60%) | William Goddard Co-Founder | 79 patents Computational chemistry tools for drug design, free‑energy calculations, and molecular modeling | 1 partnership |
| 8 | EvolutionaryScale Provider of an AI models for protein design | $142M | 23 mo ago | Seed | — | Thomas Hayes Co-Founder | — | — |
| 9 | Excelsior Sciences Developer of chemistry for automated small molecule discovery and manufacturing 72Funding top 21%Talent top 38%AI top 45%Global bottom 48% All 4 signals ▾Fundingtop 21% Talenttop 38% AItop 45% Globalbottom 48% Funding: Raised $95.0M across 2 rounds · 2 rounds over 1 yrs (2.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 72/100 | $95M | 6 mo ago | Series A | — | Michael Foley Co-Founder and Chief Executive Officer | — | — |
| 10 | Accutar Biotechnology Provider of artificial intelligence-based solutions for accelerating drug discovery and development processes | $91M | 62 mo ago | Series C | 37 | Jie Fan Founder & CEO | 145 patents Design of small‑molecule kinase degraders and computational docking for oncology drugs | — |
| 11 | Proxima Developer of a platform for programmable protein interaction-based drug discovery 42Funding top 24%Talent top 38%AI top 45%Tech bottom 45% All 6 signals ▾Fundingtop 24% Talenttop 38% AItop 45% Techbottom 45% Globalbottom 33% Marketbottom 31% Funding: Raised $86.3M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 42/100 | $86M | 5 mo ago | Seed | — | Luca Naef Co-Founder & CTO | — | — |
| 12 | Koneksa Health Digital remote health monitoring tool for providers | $71M | 52 mo ago | Series C | 104 | Chris Benko CEO | — | 3 launchs · 1 partnership |
| 13 | Castor Electronic Data Capture (EDC), eCRF, ePRO application for online data collection for medical research | $65M | 59 mo ago | Series B | 230 | Derk Arts Founder & CEO | — | — |
| 14 | Tandem AI AI-based drug discovery tool for researchers 62Funding top 27%Moat top 32%Patents top 33%Talent top 38% All 10 signals ▾Fundingtop 27% Moattop 32% Patentstop 33% Talenttop 38% Innovationtop 41% Newstop 44% AItop 45% Marketbottom 49% Techbottom 46% Globalbottom 37% Funding: Raised $60.0M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) Moat: Editorial + unicorn rating 7/10 · IP moat: 34 patents rank vs industry peers · Fliar Intelligence Index 62/100 | $60M | 7 mo ago | Series A | 200 | Jeff He Co-Founder & CEO | 34 patents Optimized photovoltaic modules with parameter matching and UV filtering for solar power systems | 1 job opening · 1 launch |
| 15 | AiCure Developer of an AI platform for patient engagement in clinical trials | $52M | 28 mo ago | Series C | 16 16 → 39 (+144%) | Gordon Kessler Co-Founder | — | — |
| 16 | Manas AI Provider of a platform for drug discovery for the treatment of cancer and rare diseases 62Funding top 24%Growth top 35%Tech top 42%AI top 45% All 7 signals ▾Fundingtop 24% Growthtop 35% Techtop 42% AItop 45% Talentbottom 49% Globalbottom 48% Marketbottom 40% Funding: Raised $50.6M across 2 rounds · 2 rounds over 1 yrs (2.0/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 62/100 | $51M | 8 mo ago | Seed | — | Siddhartha Mukherjee Co-Founder & CEO | — | — |
| 17 | Code Ocean Provider of cloud based platform for the development of algorithms | $49M | 48 mo ago | Series B | 57 | — | — | — |
| 18 | Circuit Clinical Research site network platform focuses on patient identification, enrollment, recruitment & retention | $48M | 27 mo ago | Series C | 96 | Ray Stapell Co-Founder & Special Legal Advisor | — | 1 partnership |
| 19 | Linus Biotechnology Developer of diagnostic tests for central nervous system and gastrointestinal disorders | $48M | 22 mo ago | Series A | 12 | Paul Curtin Co-Founder | 15 patents Molecular exposomics platforms and bio-surface topographic imaging for health monitoring | — |
| 20 | Envisagenics AI-driven biotechnology company that focuses on the discovery and development of novel RNA splicing… | $47M | 24 mo ago | Series B | 40 | Martin Akerman Co-Founder & CTO | 19 patents Cancer immunotherapy via neoantigen discovery and splicing‑based biomarker platforms | — |
| 21 | PreciseDx Provider of an AI-based medical image analysis software for healthcare professionals 48Talent top 23%AI top 30%Funding top 32%Moat top 48% All 8 signals ▾Talenttop 23% AItop 30% Fundingtop 32% Moattop 48% Growthbottom 42% Globalbottom 37% Marketbottom 32% Newsbottom 18% Talent: 5 named leaders on record · 5 C-suite/founder profiles curated AI: Classified as an AI company · Product described with: ai-based rank vs industry peers · Fliar Intelligence Index 48/100 | $32M | 12 mo ago | Series B | 12 | Michael Donovan Co-Founder | — | — |
| 22 | Phosphorus Provider of next-generation diagnostics and tools for clinicians and researchers | $31M | 70 mo ago | Deadpooled | 28 | — | — | — |
| 23 | Atommap Provider of physics-based and ML-augmented computational drug discovery platform 65Funding top 28%Talent top 35%Global bottom 25% All 3 signals ▾Fundingtop 28% Talenttop 35% Globalbottom 25% Funding: Raised $31.1M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 3 named leaders on record rank vs industry peers · Fliar Intelligence Index 65/100 | $31M | 3 mo ago | Series C | — | Yujie Wu Co-Founder & CTO | — | — |
| 24 | Belong Provider of an AI-based patient engagement platform for healthcare providers and clinical trail researchers | $30M | 83 mo ago | Series B | 61 | Irad Deutsch Co-Founder & CTO | — | — |
| 25 | Lokavant Provider of clinical data analytics and trial management platform for CRO | $29M | 32 mo ago | Acquired | 38 | Rohit Nambisan Co-Founder & CEO | — | — |
| 26 | Leal Provider of an AI-powered platform matching cancer patients with treatment options. | $28M | 52 mo ago | Acquired | 52 | Guy Gildor Chief Technology Officer and co-founder | — | — |
| 27 | One bio Online tools for partner management and opportunity screening. | $27M | 18 mo ago | Series A | — | Matt Barnard Co-Founder & Co-CEO | — | — |
| 28 | Anju Software Life science software platform | $26M | 92 mo ago | Acquired | 7 | — | — | — |
| 29 | Datacubed Provider of solutions for patient engagement and data management in clinical trails | $22M | 40 mo ago | Series A | 64 | Paul Glimcher Founder & Chief Scientific Officer | — | — |
| 30 | Medidata AI-based clinical trial management software for researchers | $22M | 31 mo ago | Acquired | 1,677 | Tarek Sherif Co-Founder | 228 patents AI‑driven clinical trial data management and remote physiological monitoring platforms | — |
| 31 | Ordaos Provider of an AI accelerator for biomedical research and drug discovery | $21M | 16 mo ago | Seed | 24 | Ulo Palm Md Cofounder | — | — |
| 32 | Whiz Provider of data, analytics, and technology solutions for healthcare industries | $21M | 43 mo ago | Acquired | 106 | Amitabh Patil Co-Founder & CTO | — | — |
| 33 | Auxilius Online platform for clinical trial finance management | $20M | 28 mo ago | Series A | 30 | — | — | — |
| 34 | Scope Security Cloud and AI-based cyber threat identification software for medical organizations | $20M | 54 mo ago | Deadpooled | 5 | — | — | — |
| 35 | Redesign Science Developer of protein-based small molecule drugs | $17M | 54 mo ago | Seed | 32 | David Rooklin Co-Founder & CEO | — | — |
| 36 | Dandelion Health Provider of AI-powered real-world data platform for clinical development 37Talent top 28%Funding top 34%Moat top 39%AI top 45% All 6 signals ▾Talenttop 28% Fundingtop 34% Moattop 39% AItop 45% Globalbottom 37% Marketbottom 24% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $15.9M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 37/100 | $16M | 1 mo ago | Series A | 7 | Elliott Green Co-Founder & CEO | — | 1 partnership |
| 37 | ProofPilot Platform for the development & execution of research studies 48Product top 26%Talent top 28%Innovation top 38%Moat top 39% All 9 signals ▾Producttop 26% Talenttop 28% Innovationtop 38% Moattop 39% Fundingtop 41% Techbottom 47% Marketbottom 38% Globalbottom 36% Newsbottom 17% Product: 3 distinct product lines · Company stage: Series D Talent: Analyst team rating 4/5 rank vs industry peers · Fliar Intelligence Index 48/100 | $16M | 9 mo ago | Series D | 19 | — | — | 1 launch |
| 38 | Massive Bio Provider of AI-based clinical trial management tool | $16M | 48 mo ago | Series B | 100 | Arturo Loaiza-Bonilla Md Co-Founder & Chief Medical Officer | — | 1 partnership |
| 39 | BEKHealth Provider of patient screening, recruitment, and analytics solution | $15M | 21 mo ago | Series C | 42 | Jason Baumgartner Founder & CEO | 2 patents AI-driven patient identification and recruitment for clinical trial eligibility matching. | — |
| 40 | Imprint Developer of forensic immunology research tools | $15M | 13 mo ago | Series B | — | Victor Greiff Co-Founder | — | — |
| 41 | Waypoint Digital cell therapy platform for providers | $14M | 23 mo ago | Seed | 9 | David Phizicky Co-founder and CSO | — | — |
| 42 | Yseop Provider of automated natural language generation software for regulatory writing | $13M | 30 mo ago | Series A | 84 | Alain Kaeser Co-Founder & Chief Strategy Officer | — | 2 awards |
| 43 | nemedio Provider of a quality management software for healthcare professionals | $9M | 31 mo ago | Series A | 9 | Sabrina Varanelli Founder & CEO | 2 patents Dynamic configuration software for external hardware devices | — |
| 44 | ViuHealth Provider of home healthcare services | $8M | 31 mo ago | Series A | 20 | — | — | — |
| 45 | Argon AI AI-powered insights and workflow automation for the pharmaceutical, biotech, and life sciences industries | $6M | 11 mo ago | Seed | — | Samy Danesh Co-Founder & CEO | 20 patents Inflatable cushioning pads and gas‑filled insulating foams; GNSS multipath interference mitigation systems. | — |
| 46 | Applied XL AI-based clinical record tracking and documentation tool | $6M | 39 mo ago | Seed | 10 | Scott Cohen Co-Founder | — | — |
| 47 | Inductive Bio Developer of machine learning-based platform for drug discovery and development | $4M | 14 mo ago | Series A | — | Josh Haimson Co-Founder & CEO | — | 1 launch · 1 partnership |
| 48 | RUMI Scientific Provider of proprietary human stem cell platform for screening genetic diseases | $2M | 25 mo ago | Funding Raised | 6 | Ali Brivanlou Co-Founder | — | — |
| 49 | Drug Hunter Online platform provides information related to drug discovery | $748K | 9 mo ago | Seed | 33 | — | — | — |
| 50 | CellType AI-driven platform focused on drug discovery through biological simulation | $500K | 5 mo ago | Seed | — | Ivan V Co-Founder | — | — |
Top 12 Life Sciences Tech companies in New York
#1
Seed · New York City, New York · founded 2019$86.3Mraised▾
Seed · New York City, New York · founded 2019
Developer of a platform for programmable protein interaction-based drug discovery. The company offers technologies to discover proximity modulators, including inducers, modulators, and blockers. It focuses on advancing artificial intelligence drug discovery through data generation.
Fliar Intelligence Index™ 42how this company ranks against its industry peers
Funding
top 24%Talent
top 38%AI
top 45%Tech
bottom 45%Global
bottom 33%Market
bottom 31%Funding: Raised $86.3M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Seed (Jan 2026)
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
AI: Product described with: artificial intelligence
Audience (LinkedIn): 12k LinkedIn followers — 2.1% of this cohort's audience
Funding rounds
- Jan 2026Seed$86.3M
Founders & team
Investors
DCVC, NVentures, Braidwell, Roivant Sciences, AIX Ventures, Yosemite
Tech stack
Google WorkspaceHeadless UiHstsNext.JsNext.Js App RouterNode.Js
#2
Series A · New York · founded 2024$95Mraised▾
Series A · New York · founded 2024
Developer of chemistry for automated small molecule discovery and manufacturing. It offers technology that transforms small-molecule innovation into a modular, iterative process. The technology facilitates automation, artificial intelligence integration, and use by non-specialists. It enables scaling from discovery to manufacturing. The offering includes chemical building blocks that allow automation to drive synthesis and accelerate discovery. It also provides AI-guided automated iterative synthesis and testing to maximize accuracy of models.
Fliar Intelligence Index™ 72how this company ranks against its industry peers
Funding
top 21%Talent
top 38%AI
top 45%Global
bottom 48%Funding: Raised $95.0M across 2 rounds · 2 rounds over 1 yrs (2.0/yr) · Last round Series A (Dec 2025)
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
AI: Product described with: artificial intelligence
Audience (LinkedIn): 2k LinkedIn followers
Funding rounds
- Dec 2025Series A$70M
- Dec 2025Grant (prize money)$25M
Founders & team
Investors
Deerfield, Khosla Ventures, Sofinnova Partners, Cornucopian Capital, Lilly, Illinois Ventures
#3
Series A · New York City, New York · founded 2020 · 7 employees$15.9Mraised▾
Series A · New York City, New York · founded 2020 · 7 employees
Provider of AI-powered real-world data platform for clinical development. It combines proprietary AI tools with extensive real-world patient data to accelerate clinical development and commercialization. The platform offers solutions across the product lifecycle, from early clinical research to post-approval market access. This includes tools to identify therapeutic targets, optimize patient pools for trials, generate regulatory-grade evidence, and quantify clinical and economic impact. The platform also provides AI algorithm training and validation services using diverse, multi-site datasets.
Fliar Intelligence Index™ 37how this company ranks against its industry peers
Talent
top 28%Funding
top 34%Moat
top 39%AI
top 45%Global
bottom 37%Market
bottom 24%Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Funding: Raised $15.9M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) · Last round Series A (May 2026)
Moat: Editorial + unicorn rating 7/10 · 9 curated direct competitors tracked
Audience (LinkedIn): 7k LinkedIn followers
Activity (LinkedIn): 1 partnerships (incl. InVision Medical Technology) announced in 12 mo
Funding rounds
- May 2026Series A$14M
- Dec 2023Seed$15.9M
Founders & team
Investors
Primary Venture Partner, Sharp HealthCare, Moxxie Ventures, Phoenix Venture Partners, Floating Point, Healthier Capital
#4
Series C · New York City, New York · founded 2023$31.1Mraised▾
Series C · New York City, New York · founded 2023
Provider of physics-based and ML-augmented computational drug discovery platform. It offers Silicon Therapeutics and Roivant Discovery to deliver STING agonist, potent inhibitors against oncology target, and active molecules for therapeutic degradation of target proteins.
Fliar Intelligence Index™ 65how this company ranks against its industry peers
Funding
top 28%Talent
top 35%Global
bottom 25%Funding: Raised $31.1M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series C (Mar 2026)
Talent: 3 named leaders on record
Global: Single-market focus (United States)
Audience (LinkedIn): 2k LinkedIn followers
Funding rounds
- Mar 2026Series C$31.1M
Founders & team
#5
Series A · New York, New York · founded 2021 · 200 employees$60Mraised▾
Series A · New York, New York · founded 2021 · 200 employees
AI-based drug discovery tool for researchers. The company offers a proprietary web-based platform to increase the speed of drug discovery and deliver cost-effective opportunities to the global scientific community.
Fliar Intelligence Index™ 62how this company ranks against its industry peers
Funding
top 27%Moat
top 32%Patents
top 33%Talent
top 38%Innovation
top 41%News
top 44%Funding: Raised $60.0M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) · Last round Series A (Nov 2025)
Moat: Editorial + unicorn rating 7/10 · IP moat: 34 patents · 9 curated direct competitors tracked
Patents: 34 patents matched (strict assignee match) · Lead CPC: H10F19/40 (+2 more areas)
Audience (LinkedIn): 5k LinkedIn followers
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Principal Al/Machine Learning Scientist, Drug Discovery
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- Nov 2025Series A$22M
- Mar 2023Series A$35M
- Dec 2021Seed$25M
Founders & team
Investors
Orbimed, Eight Roads Ventures, F-Prime Capital, Qiming Venture Partners, Chengwei Capital, V-Capital
Tech stack
AosCivicthemeCloudflareCloudflare Bot ManagementGoogle AnalyticsGoogle Font Api
#6
Seed · New York City, New York · founded 2025$50.6Mraised▾
Seed · New York City, New York · founded 2025
Provider of a platform for drug discovery for the treatment of cancer and rare diseases. It utilizes artificial intelligence, generative computational chemistry, and leading biology to accelerate the drug development. It customise chemical libraries and utilizes advanced AI filters to identify therapeutic candidates.
Fliar Intelligence Index™ 62how this company ranks against its industry peers
Funding
top 24%Growth
top 35%Tech
top 42%AI
top 45%Talent
bottom 49%Global
bottom 48%Funding: Raised $50.6M across 2 rounds · 2 rounds over 1 yrs (2.0/yr) · Last round Seed (Sep 2025)
Growth: Fresh capital in last 24 mo
Tech: 23 technologies across 4/8 capability areas · Cloud: Cloudflare, Vercel · Security: Hsts, Http/3
Audience (LinkedIn): 8k LinkedIn followers
Funding rounds
- Sep 2025Seed$26M
- Jan 2025Seed$24.6M
Founders & team
Investors
General Catalyst, Greylock Partners, The General Partnership, Blitzscaling Ventures, Westbound Equity, Mosaic Ventures
Tech stack
GodaddyGoogle WorkspaceHstsNext.JsNext.Js App RouterNode.Js
#7
Series D · New York City, New York · founded 2012 · 19 employees$15.7Mraised▾
Series D · New York City, New York · founded 2012 · 19 employees
ProofPilot is an online platform for the development & execution of research studies. Researchers can use ProofPilot’s comprehensive solution to design their study, recruit participants, engage participants, manage tasks, and collect study data. Studies can now be developed four times faster and require less investment of time & money. Researchers can focus on research questions and real breakthroughs rather than recruitment and logistical management. ProofPilot allows researchers to define how they want participants to engage whether it's via ProofPilot's participant platform, mobile app, paired connected device, or in a clinic-based setting.
Fliar Intelligence Index™ 48how this company ranks against its industry peers
Product
top 26%Talent
top 28%Innovation
top 38%Moat
top 39%Funding
top 41%Tech
bottom 47%Product: 3 distinct product lines · Company stage: Series D
Talent: Analyst team rating 4/5
Innovation: 3 product lines
Audience (LinkedIn): 4k LinkedIn followers
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- Sep 2025Series D$7.7M
- Jun 2024Series C$4.7M
- Apr 2022Series B$12M
- May 2016Seed$1.9M
Investors
Mitsui, Sopris Capital, First Trust Capital Partners, Excelra, Cue Ball, Brooklyn Bridge Ventures
Tech stack
Hubspot Cms HubWistiaBootstrapEnvoyHubspotJsdelivr
#8
Series B · New York City, New York · founded 2019 · 12 employees$31.5Mraised▾
Series B · New York City, New York · founded 2019 · 12 employees
Provider of an AI-based medical image analysis software for healthcare professionals. The software has AI-enabled tools that assist professionals to diagnose pathological samples for diagnosis and treatment solutions. The tool uses AI technology to analyze pathological images of the patient and predict disease, it assists in the enhancement of the image and provides workflow management solutions.
Fliar Intelligence Index™ 48how this company ranks against its industry peers
Talent
top 23%AI
top 30%Funding
top 32%Moat
top 48%Growth
bottom 42%Global
bottom 37%Talent: 5 named leaders on record · 5 C-suite/founder profiles curated
AI: Classified as an AI company · Product described with: ai-based
Funding: Raised $31.5M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) · Last round Series B (May 2025)
Audience (LinkedIn): 2k LinkedIn followers
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- May 2025Series B$11.2M
- Feb 2024Series B$20.7M
Founders & team
Investors
Eventide Asset Management, LabCorp, Quest Diagnostics, GenHenn Capital, MSD, Philips
#9
Series D · New York City, New York · founded 2016$608Mraised▾
Series D · New York City, New York · founded 2016
Provider of AI-powered drug discovery platform for various diseases. It leverages technology such as LLMs and the modern data stack in novel ways to efficiently design and operate clinical development in Atopic Dermatitis, Chronic Hand Eczema, and Knee Osteoarthritis.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 47k LinkedIn followers — 8.3% of this cohort's audience
Funding rounds
- May 2024Series D$372.2M
- Sep 2021Series C$156M
- 2018Series B$80M
- 2017Series A—
Founders & team
Investors
Thrive Capital, Sequoia Capital, Willett Advisors, Casdin Capital, Felicis Ventures, Dragoneer Investment Group
Tech stack
Amazon Web ServicesApple Icloud MailGoogle WorkspaceHstsMailgunNext.Js
#10
Seed · New York City, New York · founded 2019 · 24 employees$21.1Mraised▾
Seed · New York City, New York · founded 2019 · 24 employees
Provider of an AI accelerator for biomedical research and drug discovery. The platform provides an AI drug discovery pipeline for researchers to develop novel immunotherapies in oncology and chronic inflammatory disease.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 5k LinkedIn followers
Funding rounds
- Feb 2025Seed$337.7K
- Aug 2024Seed$3.1M
- Mar 2024Seed$5M
- Dec 2023Seed$500K
Founders & team
Investors
VTC Ventures, Route 66 Ventures, Banyan Pacific Capital, Citta Capital, IAG Capital Partners, NuFund
#11
Seed · New York City, New York · founded 2023$142Mraised▾
Seed · New York City, New York · founded 2023
Provider of an AI models for protein design. The company has developed ESM3, a frontier language model for biology that can simultaneously reason over the sequence, structure, and function of proteins.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 11k LinkedIn followers
Activity: 1 partnerships (incl. Biohub) announced in 12 mo
Funding rounds
- Jun 2024Seed$142M
Founders & team
Investors
Lux Capital, Amazon, NVentures
Tech stack
Amazon Web ServicesCloudflareGoogle AnalyticsGoogle Font ApiGoogle Hosted LibrariesGsap
#12
Series B · New York City, New York · founded 2023$15Mraised▾
Series B · New York City, New York · founded 2023
Developer of forensic immunology research tools. It builds experimental and computational tools to reconstruct immune histories from memory B and T cells. This helps uncover the causes of chronic diseases by identifying new disease mechanisms and therapeutic targets, enabling the development of diagnostics, cures, and treatments. The tools are designed to be scalable, cost-efficient, and accessible to the biomedical community. The research focuses on understanding the immune system's record of past exposures to identify hidden causes of chronic conditions like autoimmune diseases, long-COVID, psychiatric disorders, and dementia.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 1k LinkedIn followers
Funding rounds
- May 2025Series B$15M
Founders & team
Investors
Convergentresearch, NYCEDC
Funding & investor landscape
$4.1Btotal disclosed funding
87companies funded
260disclosed rounds
1rounds last 90 days
Most active investors
Y Combinator7 rounds
SV Angel5 rounds
Techstars4 rounds
Notable founders
Luca Naef
Co-Founder & CTO · Proxima
Zachary Carpenter
Co-Founder & CEO · Proxima
Marc Feiglin
Chief Technology Officer · Excelsior Sciences
Michael Foley
Co-Founder and Chief Executive Officer · Excelsior Sciences
Elliott Green
Co-Founder & CEO · Dandelion Health
Ziad Obermeyer
Co-Founder · Dandelion Health
Yujie Wu
Co-Founder & CTO · Atommap
Huafeng Xu
Founder and CEO · Atommap
Jeff He
Co-Founder & CEO · Tandem AI
Tom Tang
Co-Founder · Tandem AI
Siddhartha Mukherjee
Co-Founder & CEO · Manas AI
Michael Donovan
Co-Founder · PreciseDx
Prism market signals · United States · country-scoped Prism corpus, 2,593,976 docs
Market landscape — 10 sub-themes by coverage
Share of Life Sciences Tech coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · United States
How research on Biotechnology is moving in the United States
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 6,260 United States-affiliated papers.
research sentiment over time
200820162026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and steady — the enthusiastic (strongly-positive) share moved 44% → 42% across 2008–2026.
top research entities
- Harvard University209
- Cornell University177
- University of Tennessee at Chattanooga140
- Howard Hughes Medical Institute126
- Johns Hopkins University121
leading researchers
Stylianos Chatzimanolis · TARIK DEDOVIC · KATH-RYN ANN F. HANKINS · Christoforos Pavlou · Giannis Bolanakis · Ashley R Tetens · Tyler Findlay · Jordyn Craig-Schwartz
▲
Breakthroughs2,038 · 33%
▼ 41%→30% share
▼0.7× share momentum0 median citations71% since 2021mostly empirical
Gene-focused breakthrough research surged from 33 to 164 papers, making it the dominant rising sub-topic in a shrinking segment.
rising sub-themes (early→recent)
- Gene33→164
- Transcription (linguistics)11→79
- Antibody11→62
- Genome6→56
- Mutation7→56
Newly emergingIdentification (biology) 0→18 · Function (biology) 0→18 · Reporter gene 0→16
Landmark U1 snRNP regulates cancer cell migration and invasion in vitro · 7,224 cites
◆
Advancements2,118 · 34%
▲ 29%→35% share
▲1.2× share momentum0 median citations80% since 2021mostly empirical
Cell culture and gene expression advancements each jumped from 3 to 62 papers as the advancements segment grew from 29% to 35%.
rising sub-themes (early→recent)
- Gene8→110
- Cell culture3→62
- Gene expression3→62
- Fermentation2→54
- Downregulation and upregulation1→50
Newly emergingIdentification (biology) 0→27 · Probiotic 0→24 · Cultivar 0→23
Landmark Using Deep Learning for Image-Based Plant Disease Detection · 4,262 cites
▼
Concerns1,006 · 16%
▼ 17%→15% share
▼0.9× share momentum0 median citations73% since 2021mostly empirical
Antibiotic resistance concern papers tripled from 15 to 45, intensifying alongside newly emerging animal health and pest management topics.
rising sub-themes (early→recent)
- Agriculture19→58
- Antibiotic resistance15→45
- Public health4→31
- Gene6→30
- Production (economics)5→29
Newly emergingQuality (philosophy) 0→27 · Animal health 0→14 · Integrated pest management 0→13
Landmark The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate · 8,812 cites
RESEARCH HOTSPOTS · United States
Where biotechnology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Boston351 · +0.52
New York319 · +0.47
SF Bay Area235 · +0.57
Philadelphia115 · +0.60
San Diego101 · +0.59
Seattle95 · +0.46
Chicago95 · +0.57
Los Angeles93 · +0.61
Pittsburgh65 · +0.54
Ann Arbor65 · +0.58
PATENT SIGNAL · United States
Who's filing biotechnology patents in the United States
United States biotechnology patent filing is accelerating — 457,918 filings from 8,000 assignees (2016–2025), led by Genentech, UNIV California, Regeneron Pharma; annual filings 36884→44446.
457,918 filings8,000 assigneespeak 51616/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- Genentech18103
- UNIV California17969
- Regeneron Pharma16083
- Amgen10510
- Monsanto Technology9754
- UNIV Pennsylvania8526
- Harvard College7463
- UNIV Texas7382
Common questions
How many Life Sciences Tech companies are there in New York, United States?
Radar tracks 167 indexable Life Sciences Tech companies headquartered in New York, United States that meet our profile-completeness bar.
What is the total funding raised by Life Sciences Tech companies in New York, United States?
The Life Sciences Tech companies in New York, United States on this list have raised a combined $4.1B in disclosed equity funding across 87 funded companies.
Which is the highest-funded Life Sciences Tech company in New York, United States?
Formation Bio is the highest-funded Life Sciences Tech company in New York, United States, with $608M in disclosed equity funding.
How many Life Sciences Tech companies in New York, United States are funded?
87 of the 167 Life Sciences Tech companies in New York, United States on this list have disclosed at least one equity funding round.
How many Life Sciences Tech unicorns are there in New York, United States?
2 Life Sciences Tech companies in New York, United States on this list are valued at $1B or more.
Who are the top investors in New York, United States Life Sciences Tech companies?
The most active investors in New York, United States Life Sciences Tech companies on this list include HHS, Design Technologies, Y Combinator, Blueprint Health, Lux Capital.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.